Trial NCT05431179

View at ClinicalTrials.gov 
Org. Study IDs: ZILO-301

Last trial update was posted on 2023-04-21

MeSH Interventions

Ibrutinib

MeSH Conditions

Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Mantle-Cell Lymphoma, Non-Hodgkin Lymphoproliferative Disorders

Other Conditions


Stopping Reasons

Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape for Bruton's tyrosine kinase inhibitors (BTK inhibitors)

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID